Blood vessel growth in the skeletal system and osteogenesis seem to be coupled, suggesting the existence of molecular crosstalk between endothelial and osteoblastic cells 1, 2 . Understanding the nature of the mechanisms linking angiogenesis and bone formation should be of great relevance for improved fracture healing or prevention of bone mass loss. Here we show that vascular growth in bone involves a specialized, tissue-specific form of angiogenesis. Notch signalling promotes endothelial cell proliferation and vessel growth in postnatal long bone, which is the opposite of the well-established function of Notch and its ligand Dll4 in the endothelium of other organs and tumours 3, 4 . Endothelial-cell-specific and inducible genetic disruption of Notch signalling in mice not only impaired bone vessel morphology and growth, but also led to reduced osteogenesis, shortening of long bones, chondrocyte defects, loss of trabeculae and decreased bone mass. On the basis of a series of genetic experiments, we conclude that skeletal defects in these mutants involved defective angiocrine release of Noggin from endothelial cells, which is positively regulated by Notch. Administration of recombinant Noggin, a secreted antagonist of bone morphogenetic proteins, restored bone growth and mineralization, chondrocyte maturation, the formation of trabeculae and osteoprogenitor numbers in endothelial-cell-specific Notch pathway mutants. These findings establish a molecular framework coupling angiogenesis, angiocrine signals and osteogenesis, which may prove significant for the development of future therapeutic applications.
Dye injection and corrosion cast experiments had indicated that metaphyseal vessels in growing long bone are arranged in parallel, columnar strands with distal anastomotic interconnections 5, 6 . Improved bone processing and immunostaining (see Methods) allowed the detailed analysis of these vessels, which were straight tubules with a diameter of 5-10 mm (Fig. 1a and Extended Data Fig. 1 ). At their distal end, next to growth plate chondrocytes, columns were linked by tubular arches, which carried blind-ended, bulb-shaped protrusions with a calibre of 15-20 mm (Fig. 1a and Extended Data Fig. 2a-c) . Osterix 1 osteoblasts and their progenitors were abundant around endothelial columns (Fig. 1a) . Arch vessels extended filopodia towards the growth plate and were fully lumenized as demonstrated by Dextran perfusion (Fig. 1b) , expression of lumen markers like ICAM2 or Podocalyxin, and electron microscopy (Extended Data Fig. 2d-f) . Thus, the most distal, leading endothelial structures in long bone were not sprouts but tubular arches carrying bulb-like protrusions.
5-ethynyl-29-deoxyuridine (EdU) labelling revealed that endothelial cell (EC) proliferation predominantly occurred within metaphyseal columns and, less prominently, in arches ( Fig. 1c and Extended Data Fig. 2g ). Endomucin (Emcn), a sialoprotein expressed by non-arterial endothelial cells 7 , allowed the identification of arterioles in long bone as thin (5 mm) CD31 (Fig. 1d) . As shown in the accompanying manuscript 8 , CD31
hi Emcn hi (referred to here as type H) endothelial cells, as found in vessel columns and arches, display high proliferation rates and mediate vascular growth in bone.
Known regulators of vessel growth were highly expressed in freshly isolated type H endothelial cells relative to the much more abundant CD31 lo Emcn lo (type L) cells of the sinusoidal vasculature of the marrow cavity (Extended Data Fig. 3a) . Immunostaining confirmed high expression of Neuropilin 1, Plexin D1, Unc5b or FLT4/VEGFR3 in vessel arches and columns (Extended Data Fig. 3b-g ). These data indicate a specialized mode of angiogenesis in bone in which type H vessel arches and columns are the functional equivalent of endothelial sprouts.
Notch negatively regulates angiogenesis in embryos, murine retinas or tumours 3, 4, 9 . Notch and Delta-like 4 (Dll4), which signal in a cellcell contact-dependent fashion between endothelial cells, limit sprouting and mitosis in the growing vasculature. In long bone, Dll4 was highly expressed by arteries and vessel arches. Jagged1, another Notch ligand controlling angiogenesis, was found in vessel arches and columns, but also in perivascular mesenchymal (osteoprogenitor) cells (Extended Data Fig. 3h, i) . Inducible inactivation of the Rbpj gene encoding RBP-Jk, an essential mediator of Notch-induced gene transcription, in postnatal endothelium unexpectedly decreased CD31 hi Emcn hi vessels and the number of total and proliferating endothelial cells in long bone (Fig. 1e-i and Extended Data Fig. 4a ). The column/arch pattern was disrupted in Rbpj iDEC tibiae, and filopodia extension from mutant vessels was disorganized (Fig. 1e, g and Extended Data Fig. 4c-e Fig. 4f-h ). As Notch can positively regulate artery formation, Fbxw7 iDEC bones contained numerous small arterioles (Extended Data Fig. 5a ).
Suppression of angiogenesis by Dll4/Notch has been linked to VEGF receptor downregulation 3, 4, 9 . In Rbpj iDEC metaphyseal vessels, VEGFR1 (also known as FLT1), VEGFR2 (also known as KDR) and VEGFR3 (also known as FLT4) immunostaining was reduced, whereas Fbxw7 iDEC samples contained more labelled vessels (Extended Data Fig. 5b-d) . Transcripts for all three receptors were reduced in freshly sorted Rbpj iDEC bone endothelial cells but increased in Fbxw7 iDEC cells ( Fig. 1j and Extended Data Fig. 5e, f) . In contrast, mRNA for soluble VEGFR1 (sFlt1), which antagonises VEGF-induced signalling, was strongly elevated in Rbpj iDEC samples and decreased in Fbxw7 iDEC endothelial cells (Fig. 1k) .
Inducible, endothelial-cell-specific overexpression of the Notch1 intracellular domain (NICD) phenocopied the Fbxw7 iDEC results. CD31
hi Emcn hi vessels and small arterioles were significantly more abundant in the mutant metaphysis (Extended Data Fig. 5g, h ). Thus, although Notch inhibits vessel growth and endothelial proliferation in other organs, the pathway promotes bone angiogenesis. Expression of Notch target genes (Hey1, Hes5), modulators of angiogenesis (Jag1, Ephb4, Angpt2) and cell cycle regulators (Cdkn1a, Cdkn1b, Cdkn2a) were also different between freshly isolated lung and bone endothelial cells (Extended Data Fig. 6a-d) .
Defective angiogenesis in Rbpj iDEC mice was accompanied by shortened long bones ( Fig. 2a and Extended Data Fig. 7a ) and disorganization of the metaphysis with large, irregular lacunae (Fig. 2b) . Osteopontin immunostaining showed that mutants lacked clearly separated trabeculae and contained numerous small, highly interconnected bony elements (Fig. 2c) . Micro-computed tomography (m-CT) and histomorphometric analysis showed significant loss of bone mass and density (that is, bone volume over total volume; BV/TV), number and thickness of trabeculae, and osteoid thickness in Rbpj iDEC tibiae, without appreciable changes in bone-resorbing osteoclasts (Fig. 2d, e and Extended Data Fig. 7b-j) . Calcein double labelling showed strongly reduced bone formation rates in Rbpj iDEC bone (Fig. 2f, g ). Endothelial-specific Notch activation in Fbxw7 iDEC mutants had the opposite effect (Extended Data Fig. 7m-t) .
Osterix 1 cell numbers were significantly increased in the Rbpj iDEC metaphysis (Fig. 2h, i) Fig. 8a ). Confirming the accumulation of osteoprogenitors, primary mesenchymal cells from Rbpj iDEC bone generated mineral nodules within 10-14 days, whereas controls required 21-28 days (Extended Data Fig. 8b and data not shown). These data suggested that Notch-dependent, endothelial-cell-derived signals control osteoprogenitor differentiation. Arguing against defective oxygenation as the cause of these changes, pimonidazole and anti-HIF1a staining were not appreciably altered in Rbpj iDEC long bone (Extended Data Fig. 8c, d) .
To identify the relevant Notch ligand in bone vessels, Cdh5(PAC)-CreERT2 transgenics with endothelial-cell-specific expression of tamoxifeninducible Cre recombinase were combined with conditional Dll1 (ref. 13 ), Dll4 (ref. 14) or Jag1 (encoding Jagged1) 15 mice, respectively. Vessel growth and patterning was not visibly altered in the Dll1 iDEC or Jag1 iDEC mutant skeleton (Extended Data Fig. 8e ). Dll4 iDEC long bones were substantially shorter and phenocopied Rbpj iDEC defects (Extended Data Fig. 8f, g) , 2c and 3a) . While labelling of mitotic chondrocytes did not reveal alterations in the proliferating zone, mutant maturation/hypertrophy zones were significantly enlarged and expression of Sox9, which regulates chondrocyte differentiation and hypertrophy, was lost (Fig. 3c-e and Extended Data Fig. 8h, i) . VEGF-A expression by mature and hypertrophic chondrocytes 17 was also strongly reduced Fig. 8j, k) . The size of Fbxw7 iDEC growth plates and maturation/hypertrophy zones was reduced, whereas Sox9 expression was maintained (Extended Data Fig. 9a -c, f, g). Vegfa transcripts were elevated in Fbxw7 iDEC bone samples in sharp contrast to the reduction in Rbpj iDEC tibiae (Extended Data Fig. 9d , e). Mesenchymal Notch expression promotes proliferation and suppresses osteoblast differentiation 18, 19 . As Dll4 expression is transcriptionally regulated by Notch and RBP-Jk ) rescued the structural alterations seen in the Dll4 iDEC metaphysis and bone vasculature, enabled trabeculae formation and restored growth plate size, Sox9 expression and osteoprogenitor numbers ( Fig. 3g and Extended Data Fig. 9l-p) . Thus, endothelial-cell-specific and cell-autonomous Notch activity regulates bone angiogenesis and couples it to osteogenesis. Recent studies have highlighted the importance of angiocrine factors for organ growth and regeneration 20 . To identify potential endothelialcell-derived signals acting on osteoblastic cells, endothelial cells isolated from Fbxw7 iDEC and control bone were screened by a candidate approach. Tgfb2, Bmp4, Fgf1, Fgf8, Wnt1, Wnt3a, Wnt10b, Dkk1 and Pgf (encoding Plgf) transcripts were increased in Fbxw7 iDEC bone endothelium (Fig. 4a) . The highest upregulation (40-fold) was observed for Nog mRNA encoding Noggin, a secreted antagonist of bone morphogenetic proteins (BMPs). Other secreted BMP antagonists, namely Chordin (Chrd) and Cerberus 1 (Cer1), were not detectable in FACS-isolated bone endothelial cells (Fig. 4a) . As additional evidence for Noggin as a Notch-controlled angiocrine regulator, Nog expression was significantly reduced in purified Rbpj iDEC bone endothelial cells (Fig. 4b) . In control tibiae, Noggin immunostaining was detected in endothelial columns/arches and surrounding perivascular cells. In diaphysis, Noggin was detectable at lower level and without pronounced vessel association (Extended Data Fig.  10a, b) . Consistent with its known role in bone formation [21] [22] [23] , Noggin inhibited primary mesenchymal cell differentiation into osteoblasts in vitro (Fig. 4c) 
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formation, shortened femoral length, reduced trabeculae and oversized growth plates 22, 23 . Daily injection of Rbpj iDEC mice with recombinant Noggin protein for 2 weeks before analysis at P28 restored metaphysis organization, improved bone formation and normalized the number of osteoprogenitors (Fig. 4d-f and Extended Data Fig. 10c-f ). Exogenous Noggin also restored the organization of the Rbpj iDEC bone vasculature, growth plate size, and chondrocyte Sox9 and VEGF-A expression ( Fig. 4g and Extended Data Fig. 10g-i) .
These findings identify Notch as an important positive regulator of vascular growth in bone, which is highly distinct from the Dll4/Notchmediated suppression of endothelial cell mitosis and sprouting in other organs. Whereas previous work had already indicated that Osterix 1 cells co-invade with growing vessels in experimental bone fractures 2 , we now establish a molecular framework coupling the activity of endothelial cells, chondrocytes and osteoprogenitors. Future work will address whether Notch and other pathways can be used to promote fracture healing or prevent pathological bone loss.
METHODS SUMMARY
For wild-type bone analysis, C57BL/6J male mice were used unless stated otherwise. All endothelial-cell-specific gene targeting experiments were performed with Cdh5(PAC)-CreERT2 transgenic mice 24 . For Rbpj deletion in the postnatal endothelium, mice carrying loxP-flanked Rbpj (Rbpj lox/lox ) alleles 25 and Cdh5(PAC)-CreERT2 transgenics were interbred. To induce Cre activity and gene deletion, offspring was injected with 500 mg tamoxifen (Sigma, T5648) intraperitoneally every day from P10 to P14. The resulting Rbpj iDEC (CreERT2 T/1 Rbpj lox/lox ) mutants and Cre-littermate controls were sacrificed at P28, and femurs and tibiae were collected for analysis. Identical breeding and tamoxifen administration strategies were used to generate EC-specific mutants with iOE-EC double mutants, which received tamoxifen and were analysed as described above. For mutant analysis, both male and female mice were used.
For Noggin administration experiments, mice were injected intraperitoneally once daily with 500 mg per kg recombinant Noggin (R&D Systems) from P15 to P27, after completion of tamoxifen injections (P10-P14) and before analysis at P28.
All animal experiments were performed in compliance with the relevant laws and institutional guidelines and were approved by local animal ethics committees.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Genetically modified mice. For wild-type bone analysis, C57BL/6J male mice were used unless stated otherwise. All endothelial-cell-specific gene targeting experiments were performed with Cdh5(PAC)-CreERT2 transgenic mice 24 . For Rbpj deletion in the postnatal endothelium, mice carrying loxP-flanked Rbpj (Rbpj lox/lox ) alleles 25 and Cdh5(PAC)-CreERT2 transgenics were interbred. To induce Cre activity and gene deletion, offspring was injected with 500 mg tamoxifen (Sigma, T5648) intraperitoneally every day from P10 to P14. The resulting Rbpj iDEC (CreERT2 iOE-EC double mutants, which received tamoxifen and were analysed as described above. For mutant analysis, both male and female mice were used.
All animal experiments were performed in compliance with the relevant laws and institutional guidelines and were approved by local animal ethics committees. Immunohistochemistry. Freshly dissected tibiae were collected from wild-type and mutant mice and their control littermates and immediately fixed in 4% icecold paraformaldehyde solution for 4 h. Decalcification was carried out with 0.5 M EDTA at 4 uC with constant shaking for 24 h. Then the decalcified bones were immersed into 20% sucrose and 2% polyvinylpyrrolidone (PVP) for 24 h. Finally, the tissues were embedded and frozen in 8% gelatin (porcine) in the presence of 20% sucrose and 2% PVP and cryosectioned using low-profile blades on a Leica CM3050 cryostat.
For phenotypic analysis, mutant mice and littermate controls were always processed, sectioned, stained, imaged and analysed together at the same conditions and settings. For immunostaining, bone sections were air-dried, permeabilized for 10 min in 0.3% Triton X-100, blocked in 5% donkey serum at room temperature for 30 min. Blocked sections were probed with the primary antibodies diluted in 5% donkey serum in PBS for 2 h at room temperature or overnight at 4 uC. After primary antibody incubation, sections were washed with PBS for three times and incubated with appropriate Alexa Fluor-coupled secondary antibodies (1:400, Molecular Probes) for 1 h at room temperature. Nuclei were counterstained with DAPI. Sections were thoroughly washed with PBS before mounting them using FluoroMount-G (Southern Biotech). Finally, the slides were air-dried and sealed with nail polish.
The following primary antibodies were used: Endomucin (sc-65495, Santa Cruz, diluted 1:100), Pecam1 conjugated to Alexa Fluor488 (FAB3628G, R&D Systems, 1:100), Pecam1 (553370, BD Pharmingen, 1:100), Osterix (sc-22536-R, Santa Cruz, For visualizing vascular lumina in the angiogenic front, tetramethyl rhodamineconjugated fixable dextran of 2,000 kDa (Invitrogen, D7139) was perfused through the heart of deeply anaesthetized mice. Mice were euthanized after 10 min and bones were processed further.
For labelling of proliferating cells, mice were intraperitoneally injected with 300 mg EdU (Invitrogen) 3 h before euthanasia. Tibiae were immediately collected and processed as mentioned earlier. The bone sections were immunostained for EDU using Click-iT chemistry following the manufacturer's protocols (Invitrogen).
For metabolically labelling with the hypoxia probe pimonidazole (Pimo, Hypoxyprobe Inc.), mutant and control mice were intraperitoneally injected with 60 mg per kg Pimo for 2 h before euthanasia. Metabolized Pimo was detected by a rabbit antiserum against the non-oxidized, protein-conjugated form of pimonidazole (Hypoxyprobe Inc.). Image acquisition, processing and quantitative analysis. Immunofluorescent stainings were analysed at high resolution with a Zeiss LSM-780 laser scanning confocal microscope. Z-stacks of images were processed and 3D reconstructed with the Imaris software (version 7.00, Bitplane). Imaris, Image J, Photoshop and Illustrator (Adobe) softwares were used for image processing, in compliance with Nature's guide for digital images.
For all quantifications, a region of 300-400 mm from growth plate towards the caudal region was selected for all cell number quantifications in the metaphysis. All quantifications were done with Imaris and Image J software on high-resolution confocal images. Mesenchymal cell culture and differentiation. Primary mesenchymal cells were isolated from mouse bone and cultured following published protocols 27, 28 . In brief, freshly isolated long bones were crushed and then digested with collagenase at 37 uC for 1 h. Cells and small bone chips were washed thoroughly and cultured in 2% FBS containing alpha-MEM for few days until adherent mesenchymal cells had migrated out from the bone fragments. The adherent cells were passaged further and maintained at 37 uC with 5% CO 2 in a humidified atmosphere. For osteogenic differentiation, StemXVivo osteogenic basal medium and its supplement (RnD systems, CCM009) were used. Continuous treatment of recombinant mouse Noggin (500 ng ml
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, R&D systems) was provided to cells and, after 28 days, the appearance of mineral nodules and mesenchymal progenitors was analysed using Alizarin red and alkaline phosphatase staining, respectively. Quantitative RT-PCR (qRT-PCR). For the analysis of mRNA expression levels, pure endothelial cell fractions were flow-sorted directly into the lysis buffer of RNeasy Mini Kit (Qiagen). Total RNA was isolated according to manufacturer's protocol. A total of 100-500 ng RNA per reaction was used to generate cDNA with the iScript cDNA Synthesis System (Bio-Rad). Quantitative PCR (qPCR) was performed using TaqMan gene expression assays on ABI PRISM 7900HT Sequence Detection System. The FAM-conjugated TaqMan probes Kdr, Flt4, membrane isoform Flt1, customised sFlt1, Nrp1, Plexind1, Unc5b, Robo4, Ntn1, Ntn3, Dll4, Jag1, Efnb2, Ephb4, Hes1, Hey1, Hey2, Hes5, Icam1, Angpt2, Cdh5, Cldn5, Pecam1, Cdkn2a, Cdkn1a, Cdkn1b, Ccnd1, Cdk2, Cdk4, Tgfb1, Tgfb2, Tgfb3, Bmp2, Bmp4, Nog, Chrd, Cer1, Fgf1, Fgf8, Wnt1, Wnt3a, Wnt5a, Wnt10b, Dkk1 and Pgf were used along with TaqMan Gene Expression Master Mix (Applied Biosystems) to perform qPCR. Gene expression assays were normalized to the endogenous VICconjugated Actb probes as control. For the analysis of Bgalp, Ibsp and Vegfa expression, RNA was isolated from the whole bone samples of mutants and littermate control animals. Freshly dissected femurs were immediately flushed (to remove haematopoietic cells), crushed and then lysed in lysis buffer. RNA isolation, cDNA preparation and qPCR were performed as described above. Flow cytometry. For flow cytometric analysis of endothelial cells, femurs and tibiae were collected, cleaned thoroughly to remove the adherent muscles and then crushed in ice-cold PBS with a mortar and pestle. Whole bone marrow was digested with collagenase at 37 uC for 20 min. Cells were counted and equal numbers of cells were subjected to immunostaining. Cells were stained with biotin-coupled CD45 (BD, 553077) and Ter119 (BD, 559971) antibodies for 45 min. After washing in PBS, cells were stained with Streptavidin PE-Cy5 (BD, 554062) and CD31-conjugated with Alexa Fluor 488 (R&Dsystems, FAB3628G) for 45 min. After washing, data was acquired on FACS Aria II or FACS Canto flow cytometers and analysed using FACSDiva software (Version 6.0, BD Bioscience). For analysis and sorting of CD31 
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Calcein double labelling was performed to calculate bone formation rate (BFR) and mineral apposition rate (MAR). Mice were given intraperitoneal injections of 10 mg per kg calcein (Sigma, C0875) dissolved in 2% sodium bicarbonate solution at the tenth day and third day before euthanasia. Bones were fixed in 4% PFA, embedded in 8% gelatin and 2% PVP and cryosectioned. Single plane images were acquired from the sections using LSM 780 (Carl Zeiss). Sections were stained with von Kossa method to assess mineralized bone. Representative images show cortical bone (diaphysis about 3 mm proximally from the growth plate). Mineral apposition rates were calculated from both cortical and trabecular bones. The latter were measured at the proximal part of trabeculae relative to the angiogenic front in the metaphysis. Osteoclast surface/bone surface (Oc. S/BS; %) and osteoclast number/bone perimeter (No. Oc./B. Pm) were calculated based on Calcitonin receptor staining of bone sections.
For electron microscopy, freshly collected femurs were processed similar to the protocol published earlier 29 . In brief, fresh bone was directly transferred into 4% paraformaldehyde, 0.5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.2), cut and fixed initially for 2 h at room temperature and overnight at 4 uC. Bone was decalcified in 5% EDTA in 0.1 M cacodylate buffer (pH 7.2) for 3 days. The sample was post-fixed for 1.5 h in 1% OsmO 4 , 1.5% potassium ferrocyanide. Dehydration and embedding in epon was done under a slight vacuum. In all, 70 nm ultrathin sections of the sample were taken in the area of interest and collected on filmed single slot copper grids (Leica UC6 ultramicrotome, Vienna, Austria). Sections got counterstained with uranyl acetate and lead, and were analysed at 80 kV on a FEITecnai 12 electron microscope (FEI, Eindhoven, The Netherlands). Pictures were taken with imaging plates (Ditabis, Pforzheim, Germany). Statistics. All data are presented as mean 6 s.e.m. The significance of difference in the mean values was determined using two-tailed Student's t test unless otherwise mentioned. P , 0.05 was considered significant. In others, non-parametric oneway ANOVA was performed along with Bonferroni's multiple comparison posthoc tests to assess statistical significance with a 95% confidence interval. All calculations were performed using GraphPad Prism software. No randomization or blinding was used and no animals were excluded from analysis. Sample sizes were selected on the basis of previous experiments. Several independent experiments were performed to guarantee reproducibility of findings. iDEC mutants and control littermates. Femur length is shown in k. m-CT data (l) were used for the analysis of bone density (bone volume/total volume; BV/TV, m), connectivity density (number of connections per unit volume, n), trabecular bone separation (size of space separating trabeculae, o), trabecular number (number of trabeculae per mm length, p), and trabecular thickness (q). Data on osteoclast number per bone perimeter (r), osteoclast surface/bone surface (Osteoclast S/B S) (s), and osteiod thickness (t) are based on histomorphometrical characterization of control and mutant samples (n 5 6 mice from 4 independent litters). Error bars, 6 s.e.m. P values, two-tailed unpaired t-test.
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